JP2009535346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535346A5 JP2009535346A5 JP2009507825A JP2009507825A JP2009535346A5 JP 2009535346 A5 JP2009535346 A5 JP 2009535346A5 JP 2009507825 A JP2009507825 A JP 2009507825A JP 2009507825 A JP2009507825 A JP 2009507825A JP 2009535346 A5 JP2009535346 A5 JP 2009535346A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- aryl
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004442 acylamino group Chemical group 0.000 claims 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000001425 triazolyl group Chemical group 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 208000004930 Fatty Liver Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- -1 3-oxetanyl Chemical group 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000007976 Ketosis Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000004140 ketosis Effects 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 230000007863 steatosis Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010068271 Cystic fibrosis related diabetes Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/411,413 US7521446B2 (en) | 2005-01-13 | 2006-04-26 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| PCT/US2007/010258 WO2007127382A1 (en) | 2006-04-26 | 2007-04-25 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535346A JP2009535346A (ja) | 2009-10-01 |
| JP2009535346A5 true JP2009535346A5 (https=) | 2010-03-25 |
Family
ID=38462340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507825A Pending JP2009535346A (ja) | 2006-04-26 | 2007-04-25 | ハロアリール置換アミノプリン、その組成物及びそれによる治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7521446B2 (https=) |
| EP (1) | EP2010186B1 (https=) |
| JP (1) | JP2009535346A (https=) |
| KR (1) | KR20090013804A (https=) |
| CN (2) | CN101478972A (https=) |
| AU (1) | AU2007243287B2 (https=) |
| BR (1) | BRPI0710805A2 (https=) |
| CA (1) | CA2684999C (https=) |
| ES (1) | ES2400257T3 (https=) |
| IL (1) | IL194865A (https=) |
| MX (1) | MX2008013616A (https=) |
| NZ (1) | NZ572467A (https=) |
| WO (1) | WO2007127382A1 (https=) |
| ZA (3) | ZA200809356B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256196B1 (en) * | 2003-12-09 | 2007-08-14 | The Procter & Gamble Company | Purine cytokine inhibitors |
| US7759342B2 (en) * | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7521446B2 (en) * | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US9150507B2 (en) * | 2006-04-28 | 2015-10-06 | Shionogi & Co., Ltd. | Amine derivative having NPY Y5 receptor antagonistic activity |
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| NZ598071A (en) * | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| US20100311807A1 (en) * | 2007-03-14 | 2010-12-09 | Washington University | Methods for identifying diabetes and obesity therapeutics |
| SA08290668B1 (ar) * | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
| US20090156598A1 (en) * | 2007-12-17 | 2009-06-18 | Lebsack Alec D | Imidazolopyrimidine modulators of TRPV1 |
| WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| US8227618B2 (en) * | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
| US20130034495A1 (en) * | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
| US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| UY33779A (es) | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| US9493464B2 (en) | 2012-02-29 | 2016-11-15 | The Scripps Research Institute | Wee1 degradation inhibitors |
| WO2014175234A1 (ja) * | 2013-04-26 | 2014-10-30 | 富士フイルム株式会社 | 撮像装置及び画像表示方法 |
| KR102529049B1 (ko) | 2013-08-14 | 2023-05-08 | 노파르티스 아게 | 암의 치료를 위한 조합 요법 |
| GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| MX388321B (es) | 2014-10-06 | 2025-03-19 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
| AU2017241837B2 (en) * | 2016-04-01 | 2021-07-22 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| RS62496B1 (sr) | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu |
| CN109563095B (zh) | 2016-06-02 | 2021-10-29 | 细胞基因公司 | 动物和人抗疟剂 |
| EP3464312A4 (en) * | 2016-06-02 | 2019-11-27 | Celgene Corporation | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS |
| CN106265673B (zh) * | 2016-09-18 | 2019-09-20 | 中国农业大学 | 一种化合物的应用 |
| CN111417634A (zh) | 2017-10-04 | 2020-07-14 | 细胞基因公司 | 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法 |
| MX2020003620A (es) | 2017-10-04 | 2020-10-28 | Celgene Corp | Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida. |
| CN109384788B (zh) * | 2018-10-16 | 2021-05-14 | 成都大学 | 嘌呤系列衍生物及其制备方法和用途 |
| CN111544657B (zh) * | 2020-05-11 | 2022-01-11 | 北京大学第三医院（北京大学第三临床医学院） | 一种具有良好可打印性的细胞3d打印生物墨水制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5332744A (en) * | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
| CA2297967A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| TR200601784T2 (tr) | 1999-11-12 | 2007-01-22 | Pharmasset Ltd. | 2'-deoksi-L-nükleositlerin sentezi |
| ATE322494T1 (de) | 2000-01-07 | 2006-04-15 | Universitaire Instelling Antwe | Purin derivate, ihre herstellung und verwendung |
| AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
| CZ304344B6 (cs) | 2000-09-11 | 2014-03-19 | Novartis Vaccines & Diagnostics, Inc. | Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu |
| MXPA03009361A (es) | 2001-04-13 | 2004-01-29 | Boehringer Ingelheim Pharma | Compuestos de urea utilies como agentes anti-inflamatorios. |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US7256196B1 (en) * | 2003-12-09 | 2007-08-14 | The Procter & Gamble Company | Purine cytokine inhibitors |
| AU2005298637B8 (en) | 2004-10-29 | 2012-12-06 | Janssen Sciences Ireland Uc | HIV inhibiting bicyclic pyrimidine derivatives |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) * | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| NZ598071A (en) | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
-
2006
- 2006-04-26 US US11/411,413 patent/US7521446B2/en active Active
-
2007
- 2007-04-25 AU AU2007243287A patent/AU2007243287B2/en not_active Ceased
- 2007-04-25 MX MX2008013616A patent/MX2008013616A/es active IP Right Grant
- 2007-04-25 CN CNA2007800238554A patent/CN101478972A/zh active Pending
- 2007-04-25 EP EP07756113A patent/EP2010186B1/en active Active
- 2007-04-25 WO PCT/US2007/010258 patent/WO2007127382A1/en not_active Ceased
- 2007-04-25 CN CN201310180773.8A patent/CN103351389B/zh not_active Expired - Fee Related
- 2007-04-25 CA CA2684999A patent/CA2684999C/en not_active Expired - Fee Related
- 2007-04-25 JP JP2009507825A patent/JP2009535346A/ja active Pending
- 2007-04-25 KR KR1020087028768A patent/KR20090013804A/ko not_active Ceased
- 2007-04-25 ES ES07756113T patent/ES2400257T3/es active Active
- 2007-04-25 NZ NZ572467A patent/NZ572467A/en not_active IP Right Cessation
- 2007-04-25 BR BRPI0710805-2A patent/BRPI0710805A2/pt not_active IP Right Cessation
-
2008
- 2008-10-23 IL IL194865A patent/IL194865A/en active IP Right Grant
- 2008-10-31 ZA ZA2008/09356A patent/ZA200809356B/en unknown
-
2009
- 2009-03-16 US US12/404,413 patent/US8101588B2/en active Active
- 2009-10-22 ZA ZA2009/07418A patent/ZA200907418B/en unknown
-
2011
- 2011-04-20 ZA ZA2011/03036A patent/ZA201103036B/en unknown